Working… Menu
Trial record 22 of 70 for:    ORLISTAT

Orlistat Treatment of Crigler-Najjar Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00461799
Recruitment Status : Completed
First Posted : April 18, 2007
Last Update Posted : April 18, 2007
Erasmus Medical Center
De Najjar Stichting
Information provided by:
University Medical Center Groningen

Brief Summary:
The purpose of this study was to determine whether orlistat is effective in decreasing plasma unconjugated bilirubin levels in patients with Crigler-Najjar disease.

Condition or disease Intervention/treatment Phase
Crigler-Najjar Syndrome Drug: orlistat Not Applicable

Detailed Description:
Unconjugated hyperbilirubinemia in Crigler-Najjar (CN) disease is conventionally treated with phototherapy and/or phenobarbital. Life-long daily phototherapy has considerable disadvantages. Main problems are a decreasing efficacy with age and a profound impact of the intensive phototherapy regimen on the quality of (social) life. An alternative treatment option for unconjugated hyperbilirubinemia is based on intestinal capture of UCB by oral treatment. Particularly when plasma UCB concentrations are high as in CN disease, UCB can diffuse from the blood into the intestinal lumen across the mucosa. Intestinal capture of UCB followed by fecal excretion reduces the enterohepatic circulation of UCB and subsequently decreases plasma UCB concentration. We demonstrated in Gunn rats, the animal model for CN disease, that orlistat treatment decreases plasma UCB concentrations parallel with increased fecal fat excretion, and induces net transmucosal excretion of UCB from the blood into the intestinal lumen. In human adults, orlistat has been widely applied for treatment of obesity, without serious side effects. Recent studies in obese adolescents and prepubertal children indicate that short-term orlistat treatment is well-tolerated by children and generally has only mild side effects. In the present randomized, placebo-controlled trial we determined in patients with CN disease the effects of orlistat treatment on plasma UCB concentrations, and on fecal excretion of fat and UCB.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Orlistat Treatment of Unconjugated Hyperbilirubinemia in Crigler-Najjar Disease; A Randomized Controlled Trial
Study Start Date : September 2003
Actual Study Completion Date : January 2004

Primary Outcome Measures :
  1. decrease in plasma unconjugated bilirubin level during orlistat
  2. increase in fecal fat excretion during orlistat
  3. increase in fecal bilirubin concentration during orlistat

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with Crigler-Najjar disease above the age of 7 years

Exclusion Criteria:

  • cholestasis, chronic malabsorption syndrome, pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00461799

Layout table for location information
Erasmus University Medical Center
Rotterdam, Netherlands, 3015 GJ
Sponsors and Collaborators
University Medical Center Groningen
Erasmus Medical Center
De Najjar Stichting
Layout table for investigator information
Principal Investigator: Anja M. Hafkamp, MD University Medical Center Groningen and Erasmus University Medical Center
Study Chair: Maarten Sinaasappel, MD Erasmus Medical Center
Study Director: Henkjan J. Verkade, MD, PhD University Medical Center Groningen

Layout table for additonal information Identifier: NCT00461799     History of Changes
Other Study ID Numbers: CN-01
First Posted: April 18, 2007    Key Record Dates
Last Update Posted: April 18, 2007
Last Verified: April 2007
Keywords provided by University Medical Center Groningen:
Crigler-Najjar disease.
Unconjugated hyperbilirubinemia.
Additional relevant MeSH terms:
Layout table for MeSH terms
Crigler-Najjar Syndrome
Pathologic Processes
Hyperbilirubinemia, Hereditary
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Obesity Agents
Lipid Regulating Agents